Hangzhou Cancer Hospital
21
0
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 21 trials
100.0%
+13.5% vs industry average
5%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
PRL3-Zumab in Patients With Advanced Solid Tumors
Role: collaborator
Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma
Role: collaborator
Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients
Role: collaborator
RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma
Role: collaborator
Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer
Role: collaborator
SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC
Role: collaborator
Endothelial Injury Mechanism in Elderly Patients Undergoing Major Surgery
Role: collaborator
A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC
Role: collaborator
CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer
Role: lead
Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer
Role: lead
PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer
Role: lead
Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells
Role: lead
SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer
Role: lead
Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma
Role: lead
Apatinib for Metastatic Esophageal Cancer.
Role: lead
Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.
Role: lead
RT Plus EGFR-TKI for Wild-type NSCLC
Role: lead
A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)
Role: collaborator
CCRT for Esophageal Cancer.
Role: lead
Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma
Role: collaborator